Chris Boerner, Bristol Myers Squibb CEO (Tierney L. Cross/Bloomberg via Getty Images)
December 3, 2025 07:41 AM EST
Updated 10:06 AM
R&D
Updated: Bristol Myers pushes back Cobenfy readout after trial site 'irregularities'
Max Gelman
Senior Editor
Bristol Myers Squibb’s hotly anticipated Cobenfy readout in Alzheimer’s-associated psychosis will have to wait.
Because of “irregularities” at a “small number” of trial sites, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER